RA Capital Management, L.P. Files Schedule 13G for C4 Therapeutics, Inc.

RA Capital Management, L.P., along with Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P., filed a Schedule 13G with the SEC on October 24, 2025, disclosing beneficial ownership of 9,441,256 shares of common stock in C4 Therapeutics, Inc. This represents 9.9% of the company's outstanding shares. The filing indicates that RA Capital Healthcare Fund, L.P. directly holds 8,000,000 shares of common stock, along with warrants exercisable for additional shares. The warrants contain provisions that limit the Fund's ability to exercise them if it would result in ownership exceeding 9.99% of the common stock. RA Capital Management, L.P. serves as the investment adviser for the Fund and may be deemed a beneficial owner of the securities held by the Fund. Peter Kolchinsky and Rajeev Shah, as managers of RA Capital, may also be deemed beneficial owners. The filing includes a Joint Filing Agreement, indicating that the parties agree to file a single statement on Schedule 13G and/or 13D on behalf of each of them.